Schechter Investment Advisors LLC Sells 9,154 Shares of Grifols, S.A. (NASDAQ:GRFS)

Schechter Investment Advisors LLC lessened its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 9.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 88,245 shares of the biotechnology company’s stock after selling 9,154 shares during the quarter. Schechter Investment Advisors LLC’s holdings in Grifols were worth $1,020,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GRFS. Capital World Investors raised its holdings in shares of Grifols by 15.2% during the first quarter. Capital World Investors now owns 17,172,143 shares of the biotechnology company’s stock valued at $200,571,000 after acquiring an additional 2,265,005 shares in the last quarter. Norges Bank purchased a new stake in Grifols in the fourth quarter worth $19,218,000. Point72 Asset Management L.P. purchased a new stake in Grifols in the second quarter worth $17,484,000. Bank of America Corp DE grew its stake in Grifols by 69.9% in the first quarter. Bank of America Corp DE now owns 4,274,707 shares of the biotechnology company’s stock worth $31,505,000 after purchasing an additional 1,759,321 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in Grifols by 122.0% in the second quarter. Goldman Sachs Group Inc. now owns 3,048,969 shares of the biotechnology company’s stock worth $36,222,000 after purchasing an additional 1,675,639 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on GRFS. Deutsche Bank Aktiengesellschaft cut Grifols from a “hold” rating to a “sell” rating in a research note on Tuesday, March 12th. JPMorgan Chase & Co. upped their price target on Grifols from $10.00 to $10.50 and gave the stock a “neutral” rating in a research note on Tuesday, December 5th.

Grifols Price Performance

NASDAQ GRFS opened at $6.65 on Thursday. Grifols, S.A. has a 12 month low of $5.30 and a 12 month high of $12.15. The stock’s fifty day moving average price is $7.50 and its 200-day moving average price is $8.71. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.83 and a quick ratio of 1.32.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product.